

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Von Der Kammer *et al.*

Appl. No.: 10/520,065 (U.S. Nat'l Phase
of PCT/EP03/07173)

I.A. Filing Date: July 4, 2003

For: **Diagnostic and Therapeutic Use
of TB2 Gene and Protein for
Neurodegenerative Diseases**

Confirmation No.: 5124

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 2335.0040001/SRL/KPQ

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents NPL1 to NPL18 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents US1 to US6, cited on the attached IDS Forms are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Katrina Y. Pei Quach
Agent for Applicants
Registration No. 51,063

Date: September 29, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/520,065 (U.S. Nat'l Phase of PCT/EP03/07173)
				I.A. Filing Date	July 4, 2003
				First Named Inventor	Heinz VON DER KAMMER
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	2335.0040001/SRL/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Bertram, L., <i>et al.</i> , "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q," <i>Science</i> 290:2302-2303, American Association for the Advancement of Science (2000)	
	NPL2	Calero, M., <i>et al.</i> , "Yop1p, the Yeast Homolog of the Polyposis Locus Protein 1, Interacts with Yip1p and Negatively Regulates Cell Growth," <i>J. Biol. Chem.</i> 276:12100-12112, The American Society for Biochemistry and Molecular Biology, Inc. (April 2001)	
	NPL3	Joslyn, G., <i>et al.</i> , "Identification of Deletion Mutations and Three New Genes at the Familial Polyposis Locus," <i>Cell</i> 66:601-613, Cell Press (1991)	
	NPL4	Kawai, J., <i>et al.</i> , "Correspondence of RLGS-M Spot behavior with Tissue Expression on Mouse Homologue of DP1/TB2 Gene," <i>Biochem. Biophys. Res. Commun.</i> 213:967-974, Academic Press, Inc. (1995)	
	NPL5	Kinzler, K.W., <i>et al.</i> , "Identification of FAP Locus Genes from Chromosome 5q21," <i>Science</i> 253:661-665, American Association for the Advancement of Science (1991)	
	NPL6	Leroy, K., <i>et al.</i> , "Increase of adenomatous polyposis coli immunoreactivity is a marker of reactive astrocytes in Alzheimer's disease and in other pathological conditions," <i>Acta Neuropathol.</i> 102:1-10, Springer-Verlag (June 2001)	
	NPL7	Myers, A., <i>et al.</i> , "Susceptibility Locus for Alzheimer's Disease on Chromosome 10," <i>Science</i> 290:2304-2305, American Association for the Advancement of Science (2000)	
	NPL8	Prieschl, E.E., <i>et al.</i> , "The murine homolog of TB2/DPI, a gene of the familial adenomatous polyposis (FAP) locus," <i>Gene</i> 169:215-218, Elsevier Science B.V. (1996)	
	NPL9	Roses, A.D., "Apolipoprotein E and Alzheimer's Disease," <i>Ann. N.Y. Acad. Sci.</i> 855:738-743, New York Academy of Sciences (1998)	
	NPL10	Scott, W.K., <i>et al.</i> , "Fine Mapping of the Chromosome 12 Late-Onset Alzheimer Disease Locus: Potential Genetic and Phenotypic Heterogeneity," <i>Am. J. Hum. Genet.</i> 66:922-932, University of Chicago Press (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/520,065 (U.S. Nat'l Phase of PCT/EP03/07173)
				I.A. Filing Date	July 4, 2003
				First Named Inventor	Heinz VON DER KAMMER
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	2335.0040001/SRL/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Shen, Q., <i>et al.</i> , "The stress- and abscisic acid-induced barley gene <i>HVA22</i> : developmental regulation and homologues in diverse organisms," <i>Plant Molec. Biol.</i> 45:327-340, Kluwer Academic Publishers (February 2001)	
	NPL12	Strittmatter, W.J., <i>et al.</i> , "Apolipoprotein E: High-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease," <i>Proc. Natl. Acad. Sci. USA</i> 90:1977-1981, National Academy of Science (1993)	
	NPL13	Trouche, D., <i>et al.</i> , "The CBP co-activator stimulates E2F1/DP1 activity," <i>Nucl. Acids Res.</i> 24:4139-4145, Oxford University Press (1996)	
	NPL14	NCBI Entrez, GenBank Report, Accession No. Q00765, Joslyn, G. <i>et al.</i> , (first available 1993, last modified May 2005)	
	NPL15	NCBI Entrez, GenBank Report, Accession No. AAH00232, Strausberg, R.L. <i>et al.</i> , (first available February 2001, last modified June 2005)	
	NPL16	NCBI Entrez, GenBank Report, Accession No. BC000232, Strausberg, R.L. <i>et al.</i> , (first available February 2001, last modified June 2005)	
	NPL17	"Chromosome 5 open reading frame 18," <i>GeneReport</i> , No. D5S346, provided by the Genetics Department, Stanford University (2000)	
	NPL18	Copy of International Search Report for International Application No. PCT/EP03/07173, mailed November 10, 2003	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.